Urinary serotonin level is associated with serotonin syndrome after moclobemide, sertraline, and citalopram overdose

Clinical Toxicology

Volumn 45, Issue 5, 2007, Pages 458-460

  Brvar, Miran ^a   Stajer, Dusan ^a   Kozelj, Gordana ^b   Osredkar, Josko ^a   Mozina, Martin ^a   Bunc, Matjaz ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Citalopram; Diagnosis; Moclobemide; Serotonin syndrome; Sertraline; Urinary serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; CREATININE; DIAZEPAM; MIDAZOLAM; MOCLOBEMIDE; PROPOFOL; SEROTONIN; SERTRALINE; VECURONIUM;

ADULT; AGITATION; ANESTHESIA; ARTICLE; ARTIFICIAL VENTILATION; BLOOD LEVEL; CASE REPORT; CLONUS; COMATOSE PATIENT; CONTINUOUS INFUSION; DIAPHORESIS; FEMALE; HUMAN; HYPERREFLEXIA; HYPERTENSION; HYPERTHERMIA; INGESTION; INTUBATION; MUSCLE RELAXATION; MYDRIASIS; NYSTAGMUS; PARALYSIS; SEROTONIN SYNDROME; SUICIDE ATTEMPT; TACHYCARDIA; TACHYPNEA; TREMOR; TRISMUS; URINE LEVEL;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; OVERDOSE; SEROTONIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUICIDE, ATTEMPTED;

EID: 34248593038     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650601118101     Document Type: Article

References (11)

1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-1120.
2. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28:205-214.
3. Kolecki P. Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks. J Toxicol Clin Toxicol 1997; 35:211-212.
4. Brubacher JR. Treating the serotonin syndrome - antidote or support? J Toxicol Clin Toxicol 1997; 35:213-214.
5. Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003; 56:441-450.
6. Bramness JG, Morland J, Sorlid HK, Rudberg N, Jacobsen D. Carisoprodol intoxications and serotonergic features. Clin Toxicol 2005; 43:39-45.
7. Nisijima K. Abnormal monoamine metabolism in cerebrospinal fluid in a case of serotonin syndrome. J Clin Psychopharmacol 2000; 20:107-108.
8. Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Eur J Pediatr 2003; 162:723-724.
9. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancyon serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720-726.
10. Dingemanse J, Wallnofer A, Gieschke R, Guentert T, Amrein R. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome". Clin Pharmacol Ther 1998; 63:403-413.
11. Cohen ML, Brody TM. 5-Hydroxytryptamine (Serotonin) and therapeutic agents that modulate serotonergic neurotransmition. In: Brody TM, Larner J, Minneman KP, eds. Human pharmacology: molecular to clinical. 3rd ed. St. Luis, Mosby-Year Book, 1998:157-167.